1 week ago
30
A Moderna experimental vaccine tailored to each patient's tumor cut odds of deadly skin cancer returning — and new five-year data shows the results holding.
CLEVELAND — Melanoma is the deadliest form of skin cancer. Even after surgery, about half of patients see the disease return within five years — a sobering reality that has driven researchers to look beyond standard treatment.
Now, a personalized mRNA vaccine combined with immunotherapy is showing results that could change that picture.
